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factor for repeat RS was penetrating disease with vs. without 
PA (HR = 3.17 vs. 2.24; p < 0.05).  Conclusion: The risk of RS 
was confirmed to be very high for CD in our cohort. Smoking 
status at diagnosis, but mostly penetrating and stricturing 
diseases increase the risk of RS. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 About 80% of Crohn’s disease (CD) patients undergo 
resection surgery (RS) during the lifetime course of their 
disease  [1–4] . Of those undergoing surgery, repeat RS is 
needed in 11–32% of cases after 5 years and 20–44% after 
10 years  [5–7] , depending on the anatomic site involved. 
Those with ileal or ileocolonic involvement require sur-
gery more frequently. Structural bowel damage occurs 
progressively in CD patients over time  [8] . Later compli-
cations, including bowel obstruction, intra-abdominal 
abscesses or fistulas, need to be treated surgically  [9, 10] .
 Prevention of disease progression and postoperative 
recurrence are thus particularly important in CD manage-
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 Abstract 
 Background: About 80% of patients with Crohn’s disease 
(CD) require bowel resection and up to 65% will undergo a 
second resection within 10 years. This study reports clinical 
risk factors for resection surgery (RS) and repeat RS.  Meth-
ods: Retrospective cohort study, using data from patients 
included in the Swiss Inflammatory Bowel Disease Cohort. 
Cox regression analyses were performed to estimate rates 
of initial and repeated RS.  Results: Out of 1,138 CD cohort 
patients, 417 (36.6%) had already undergone RS at the time 
of inclusion. Kaplan-Meier curves showed that the proba-
bility of being free of RS was 65% after 10 years, 42% after 
20 years, and 23% after 40 years. Perianal involvement (PA) 
did not modify this probability to a significant extent. The 
main adjusted risk factors for RS were smoking at diagnosis 
(hazard ratio (HR) = 1.33; p = 0.006), stricturing with vs. with-
out PA (HR = 4.91 vs. 4.11; p < 0.001) or penetrating disease 
with vs. without PA (HR = 3.53 vs. 4.58; p < 0.001). The risk 
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ment and this includes recognition of risk factors and ag-
gressive therapy. Clinical risk factors for the first major 
resection have not wholly been identified or understood; 
those currently known are active smoking status, perforat-
ing disease phenotype and ileal involvement  [11–14] . 
Moreover, there is no consensus concerning medical 
treatments and strategies that may modify disease pro-
gression or contribute to increasing the time to first sur-
gery. Aminosalicylates, immunomodulators or biological 
therapies have shown small, uncertain or inconsistent de-
grees of benefit  [6, 14–16] . 
 The Swiss Inflammatory Bowel Disease Cohort 
 (SIBDC), one of the largest national cohorts in Europe, 
contains demographic, clinical and treatment data on 
prevalent and incident cases of CD patients in Switzerland. 
The aim of the study is to describe which CD patients un-
dergo RS and to assess factors associated with time to the 
first episode and to subsequent episodes of intestinal RS. 
 Materials and Methods 
 Study Design and Population 
 A full description of the cohort profile has been published pre-
viously  [17] , key elements are presented below. This is a retro-
spective cohort study on patients included in the SIBDC, a na-
tional prospective clinical cohort that began in 2006. SIBDC has 
four main study goals, namely to study (1) the genetic, biological 
and environmental risk factors associated with the course of the 
disease, (2) the associations with and influences of psychosocial 
factors on the recurrence of clinical symptoms, (3) the appropri-
ateness of therapy, and (4) the assessment of medical and hospital 
resource consumption by inflammatory bowel disease (IBD) pa-
tients. Patients were recruited through their gastroenterologist in 
private practices, regional hospitals and tertiary centers. Inclu-
sion criteria were a diagnosis of CD established at least 4 months 
before inclusion and confirmed by radiological, endoscopic or 
surgical assessment, or after at least one recurrence of the disease. 
CD case ascertainment was made based on the Lennard-Jones 
criteria  [18] . Patients were excluded if they suffered from another 
form of colitis, were not regularly followed up for CD, had no 
permanent residency in Switzerland or if they refused to sign the 
informed consent form. The study population consists of adult 
patients (>16 years old) included in the cohort from November 
2006 to July 2011, with a diagnosis of CD. 
 Exposure and Outcome Variables 
 Clinical data were collected during the medical visit at inclusion 
by means of clinical reporting forms completed by the patient’s gas-
troenterologist or by trained study nurses. Retrospective data since 
diagnosis were retrieved from patient charts. Data were collected on 
paper and sent to the cohort data center for data entry, checking and 
validation. The following information was used as exposure vari-
ables: patient demographics (age, gender), clinical status at inclu-
sion (CDAI score, disease location and drug therapies), and past 
medical history (date of diagnosis, disease location at diagnosis, 
smoking status at diagnosis, presence of fistulas and/or stenosis, 
history of RS). The CDAI score was categorized as follows: <150 
(remission), 150–300 (mild to low-moderate activity), and >300 
(high-moderate to severe activity). Information on smoking status 
was retrieved from patient self-administrated questionnaires, com-
pleted at inclusion and treated as a binary variable. Age at diagnosis, 
disease location and phenotype were treated as categorical vari-
ables, according to the Montreal classification  [19] . We described 
duration of disease in three categories (<5, 5 to <10, and  ≥ 10 years) 
and analyzed drug exposure according to five main categories, re-
flecting the step-up approach that is used in Switzerland. Taking 
into account past and current drug exposure, these were defined as: 
type 5 (received infliximab, adalimumab or certolizumab), type 4 
(received azathioprine, 6-mercaptopurine or methotrexate; never 
received biologicals), type 3 (received 5-ASA or antibiotics; never 
received immunomodulators; never received biologicals), type 2 
(received steroids; never received 5-ASA or antibiotics; never re-
ceived immunomodulators; never received biologicals), and type 1 
(patient who has never received any drug, ‘wait-and-see’ approach).
 The main outcome variable was having a first episode of RS 
since the diagnosis was established. The first episode of RS could 
also be the event that led to establishment of the diagnosis. The 
secondary outcome was repeat RS, defined as having had two or 
more resections since diagnosis. Both outcomes were considered 
as binary variables. For each episode of surgery, type and month/
year when performed were noted. Intestinal resection referred to 
any complete or partial ablation of an intestinal segment. In the 
case of several resections indicated at different intestinal sites, but 
at the same month/year, this was considered as the same operation. 
Indeed, due to the precision of the information collected, it was not 
possible to assess re-operation if performed within too short a 
timeframe. We assumed the number of re-operations to be small, 
thus the rates of repeat surgery not to be affected to a high extent. 
Surgery for simple fistulas, perianal abscesses (fistulectomy, fistu-
lotomy, abscess drainage, seton, mucosal sliding flaps, fibrin glue 
instillation), adhesiolysis, appendicectomy and cholecystectomy 
were not considered in the context of this study. 
 Statistical Analysis 
 We described and compared the demographic, clinical and phe-
notypic characteristics of patients who had undergone RS versus 
those who had not, and of those who had undergone only one resec-
tion versus two or more. We used cross-tabulations, with numbers 
and percentages, for categorical variables, and χ 2 tests to test the null 
hypothesis of no association between outcomes and these variables. 
The mean and standard deviation (SD) of patient age at inclusion 
in the cohort was calculated and Z tests performed to test the null 
hypothesis of no difference in drug exposure proportions between 
patients having had one RS and those having had repeated RS.
 Kaplan-Meier curves were used to describe and compare time 
to first RS and time to repeat RS according to age at diagnosis, 
disease location at diagnosis, and disease phenotype. Univariate 
Cox regression analyses were carried out to assess the strength of 
the association between (1) rates of surgery or (2) rates of repeat 
surgery and the following independent risk factors: age at diag-
nosis, gender, duration of disease, smoking status at diagnosis, 
disease location at diagnosis, and disease phenotype. In our da-
taset, the starting date of past treatments and detailed chronology 
of drug treatments were not available for all patients, therefore 
these parameters could not be included as risk factors in these 
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Table 1.  Demographic and clinical characteristics of CD patients included in the study
All postoperative patients for repeat surgery
 All patients for surgery
total no 
surgery
1 or more 
surgeries
only
1 surgery
more than 
1 surgery
All patients 1,138 721 (63.4) 417 (36.6) 293 (70.3) 124 (29.7)
Gender
Female 598 (52.5) 381 (52.8) 217 (52.0) 149 (50.9) 68 (54.8)
Mean (SD) age at inclusion visit 41 (15) 38 (15) 45 (14) 44 (14) 47 (13)
CDAI at inclusion visit
<150 854 (75.0) 575 (87.7) 279 (79.5) 210 (82.7) 69 (71.1)
150–300 143 (12.6) 77 (11.7) 66 (18.8) 42 (16.5) 24 (24.7)
>300 10 (0.9) 4 (0.6) 6 (1.7) 2 (0.8) 4 (4.1)
Maximum drug exposure since diagnosis
Type 5 308 (27.1) 201 (27.9) 107 (25.7) 62 (21.2)* 45 (36.3)*
Type 4 623 (54.7) 381 (52.8) 242 (58.0) 179 (61.1)** 63 (50.8)**
Type 3 166 (14.6) 112 (15.5) 54 (13.0) 40 (13.7) 14 (11.3)
Type 2 32 (2.8) 22 (3.1) 10 (2.4) 8 (2.7) 2 (1.6)
Type 1 9 (0.8) 5 (0.7) 4 (1.0) 4 (1.4) 0 (0.0)
Smoking status at inclusion
No 671 (59.1) 433 (60.2) 238 (57.2) 168 (57.5) 70 (56.5)
Yes 464 (40.9) 286 (39.8) 178 (42.8) 124 (42.5) 54 (43.6)
Age at diagnosis
≤16 years 123 (10.8) 75 (10.4) 48 (11.5) 25 (8.5) 23 (18.6)
17–40 years 804 (70.7) 498 (69.1) 306 (73.4) 216 (73.7) 90 (72.6)
>40 years 211 (18.5) 148 (20.5) 63 (15.1) 52 (17.8) 11 (8.9)
Duration of disease
<5 years 431 (37.9) 376 (52.2) 55 (13.2) 54 (18.4) 1 (0.8)
5 to <10 years 214 (18.8) 150 (20.8) 64 (15.3) 54 (18.4) 10 (8.1)
≥10 years 493 (43.3) 195 (27.0) 298 (71.5) 185 (63.1) 113 (91.1)
Smoking status at diagnosis
No 534 (48.2) 360 (51.5) 174 (42.4) 123 (42.6) 51 (42.2)
Yes 575 (51.8) 339 (48.5) 236 (57.6) 166 (57.4) 70 (57.9)
Disease location at diagnosis
Terminal ileum 239 (22.9) 155 (23.4) 84 (22.0) 60 (22.1) 24 (21.8)
Colonic 265 (25.4) 200 (30.2) 65 (17.0) 53 (19.5) 12 (10.9)
Ileocolonic 531 (50.9) 302 (45.6) 229 (60.0) 156 (57.4) 73 (66.4)
Upper GI tract only 9 (0.9) 5 (0.8) 4 (1.1) 3 (1.1) 1 (1.0)
Latest disease location
Terminal ileum 324 (29.2) 183 (26.0) 141 (34.8) 94 (32.9) 47 (39.5)
Colonic 354 (31.9) 261 (37.1) 93 (23.0) 65 (22.7) 28 (23.5)
Ileocolonic 420 (37.9) 256 (36.4) 164 (40.5) 124 (43.4) 40 (33.6)
Upper GI tract only 11 (1.0) 4 (0.6) 7 (1.7) 3 (1.0) 4 (3.4)
Disease phenotype
Non-stricturing/non-penetrating 522 (45.9) 459 (63.7) 63 (15.1) 53 (18.1) 10 (8.1)
Non-stricturing/non-penetrating
with perianal disease 101 (8.9) 80 (11.1) 21 (5.0) 15 (5.1) 6 (4.8)
Stricturing 204 (17.9) 82 (11.4) 122 (29.3) 94 (32.1) 28 (22.6)
Stricturing with perianal disease 70 (6.2) 18 (2.5) 52 (12.5) 33 (11.3) 19 (15.3)
Penetrating 153 (13.4) 50 (6.9) 103 (24.7) 70 (23.9) 33 (26.6)
Penetrating with perianal disease 88 (7.7) 32 (4.4) 56 (13.4) 28 (9.6) 28 (22.6)
 Values are numbers and percentages, unless specified otherwise. Z tests to test the null hypothesis of no difference in drug exposure 
between patients having had 1 RS and those having had >1 RS were made with the following results: * p < 0.001, ** p = 0.05, otherwise 
non-significant.
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analyses. Hazard ratio (HR) and 95% confidence intervals (CI) 
were calculated. Statistical significance was assessed by p value 
from likelihood ratio testing <0.05. Multivariate Cox regression 
analyses were then performed to determine the most suitable 
model for rates of surgery and rates of repeat surgery. Interaction 
between smoking status at diagnosis and other risk factors was 
assessed by comparing models with and without interaction 
terms. The accuracy of models’ prediction using Harrell’s C con-
cordance coefficient was examined  [20] . Analyses were per-
formed using STATA software version 12.1 (StataCorp, College 
Station, Tex., USA). 
 Ethical Considerations 
 The study was approved by the respective ethics committees of 
the Swiss regions from which patients were recruited. Written in-
formed consent was obtained from each participating patient.
 Results 
 Baseline Description of the Study Population 
 The total number of adult CD patients included in the 
study by July 2011 was 1,138; 598 were females (52.6%). 
Mean (SD) age at inclusion was 41 (15) years. One third 
(n = 417; 36.6%) had had RS ( table 1 ) and a third of them 
(n = 124; 29.7%) had undergone repeat RS, i.e. two or 
more operations. Mean (SD) age at first surgery was 34 
(13) years, slightly earlier in females than in males (33 vs. 
35; p = 0.045). 60% of patients with  ≥ 10 years of disease 
duration had RS and 38 of those had undergone repeat 
surgery. 82% of patients with ileal involvement at diag-
nosis, mainly ileocolonic, had RS. Most recent disease 
locations, recorded at the time of inclusion in the cohort, 
tended to shift towards the terminal ileum among pa-
tients having had one or more RS, when compared with 
location at diagnosis. A large majority of patients who 
had not undergone resection had non-stricturing/non-
penetrating CD. Regarding overall drug exposure of CD 
patients who underwent RS, we observed that drug expo-
sure that included biologicals (type 5) were more often 
prescribed to patients who had had two or more resec-
tion surgeries (36.3 vs. 21.1%; p < 0.001). The types of 
surgery performed by disease phenotype of CD patients 
are shown in  table 2 . A total of 775 surgical procedures 
were documented, the majority of them among patients 
with penetrating or stricturing disease. Resection was 
performed most often in the presence of ileocecal (32.3%) 
or ileal disease (18.7%).
 Time-to-Event Analyses for First and Repeat RS 
 65% of patients were free of RS after 10 years, 42% after 
20 years, and 23% after 40 years ( fig. 1 a). Among those 
who had surgery, almost 15% went on to a have a repeat 
operation after 5 years ( fig. 1 b). 29% of patients had re-
peat surgery after 10 years and 47% remained free of re-
peat surgery after 20 years.
 Rates of RS and Age at Diagnosis 
 Patients who were diagnosed at age  ≥ 17 had a higher 
probability of having RS during the first 15 years after 
diagnosis, but a lower probability after 15 years, com-
pared to those diagnosed before the age of 17 ( fig. 2 a). 
Table 2.  Types of surgery according to phenotype for CD patients
Type of surgery Total
n (%)
Non-stricturing/
non-penetrating (B1)
Stricturing
(B2)
Penetrating
(B3)
Perianal 
disease1
Ileocecal resection 250 (32.3) 48 113 89 76
Ileal resection 145 (18.7) 18 69 58 38
Right colectomy 105 (13.5) 24 35 46 42
Left colectomy 54 (7.0) 14 16 24 24
Sigmoid resection 22 (2.8) 1 3 18 6
Ileostomy 62 (8.0) 11 15 36 31
Colostomy 31 (4.0) 5 2 24 14
Subtotal colectomy 29 (3.7) 8 4 17 10
Total proctocolectomy 13 (1.7) 3 5 5 8
Proctectomy 8 (1.0) 1 1 6 2
Other small bowel resection 35 (4.5) 2 13 20 12
Stricturoplasty 21 (2.7) 1 7 13 9
Total, n (%) 775 (100.0) 136 (17.5) 283 (36.5) 356 (46.0) 272 (35.1)
 Values are numbers, unless specified otherwise. 1 Presence of perianal disease in any B1-B3 category.
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The proportion of patients remaining free of RS was 85% 
after 5 years, respectively 32% after 20 years, if diagnosed 
at age <17 compared to 75%, respectively 40% if diag-
nosed after the age of 17. No differences in the likelihood 
of RS were observed between those who were diagnosed 
within the range of age 17–40 and after the age of 40. 
Time to repeat surgery was shorter among patients diag-
nosed <17 years compared to those diagnosed later 
( fig. 2 b); 50% underwent repeat surgery 12 years after the 
first resection versus 21 years among those diagnosed 
aged 17–40 years.
 Rates of RS and Disease Location at Diagnosis 
 The likelihood of RS was higher among groups of pa-
tients with a disease located in the terminal ileum at diag-
nosis, 65% at 20 years versus 48% for isolated colonic dis-
ease ( fig. 2 c). In the first 5 years following a first RS, the 
probability of being free of repeat surgery was higher for 
patients with ileal involvement at diagnosis compared to 
those with isolated colonic disease; this tendency was in-
verted after 10 years ( fig. 2 d).
 Rates of RS and Disease Phenotype 
 Either stricturing or penetrating disease greatly in-
creased the probability of requiring RS compared to inflam-
matory-only disease: 60 vs. 15% at 10 years and 80 vs. 25% 
at 20 years ( fig. 2 e). Time to repeat RS for 40% of the patients 
with penetrating disease was 11 years compared to 16 years 
for those with stricturing disease and 22 years for those with 
non-stricturing/non-penetrating disease ( fig. 2 f).
 Risk Factors for RS and Repeat RS 
 Table  3 presents the results of crude and adjusted 
HRs for initial RS according to the following indepen-
dent factors: gender, age at diagnosis, smoking status at 
diagnosis, disease location at diagnosis, and disease 
phenotype. 
 We observed that crude HRs for initial RS among 
smokers at diagnosis increased by 36% (p = 0.002) com-
pared to non-smokers; a colonic-only disease location 
and having a stricturing or penetrating disease were also 
identified as crude risk factors for initial RS. After adjust-
ment for all risk factors, smoking at diagnosis remained 
a risk factor contributing to the most predictable model. 
Rates of RS were 4–5 times higher for stricturing and 
penetrating disease (p < 0.001). The presence of disease 
with perianal involvement (PA) did not change the rate 
of RS to a major extent compared to disease without PA, 
whatever the phenotype. For non-stricturing/non-pene-
trating and stricturing disease, the rate of RS further 
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 Fig. 1. Kaplan-Meier survival curve for CD patients who had not undergone RS ( a ) or repeat RS ( b ). 
 Fig. 2.  a–f Kaplan-Meier survival curve for CD patients who had 
not undergone RS according to age at diagnosis ( a ), location of 
disease ( c ), disease phenotype ( e ) or who had not undergone re-
peat RS according to age at diagnosis ( b ), location of disease ( d ), 
and disease phenotype ( f ). Location of disease is abbreviated as 
follows: terminal ileum (L1), colonic (L2), ileocolonic (L3), and 
upper GI tract only (L4); disease phenotype is abbreviated as fol-
lows: non-stricturing/non-penetrating (B1), non-stricturing/non-
penetrating with PA (B1p), stricturing (B2), stricturing with PA 
(B2p), penetrating (B3), and penetrating with PA (B3p). 
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slightly increased in the presence of PA (HR = 1.47 vs. 
1.00 and HR = 4.91 vs. 4.11), but slightly decreased for 
penetrating disease (HR = 3.53 vs. 4.58). Harrell’s C con-
cordance coefficient was 0.54 for the model with smok-
ing status at diagnosis only, 0.57 for location at diagnosis 
only, and 0.69 for disease phenotype only. The concor-
dance coefficient for the multivariate model was 0.72, 
showing there was a good relationship between the prog-
nostic score, considering these variables, and survival 
time. Results of crude and adjusted HRs for repeat RS 
according to the same potential risk factors are shown in 
 table 4 . Phenotype, especially penetrating disease, with 
or without PA, remained the sole independent risk factor 
for repeat surgery (HR = 3.17, p = 0.026 vs. 2.24; p = 
0.002). Harrell’s C concordance coefficient for the pre-
dictive model with disease phenotype was 0.61.
 Discussion 
 About one third (36.6%) of SIBDC CD patients had RS 
since diagnosis; half of which had  ≥ 2 operations. The rate 
of RS increased from 35% after 10 years since disease di-
agnosis to 77% after 40 years. Time to repeat RS for pa-
tients with penetrating disease was 11 years compared to 
16 years for stricturing disease and 22 years for non-stric-
turing/non-penetrating disease. Independent risk factors 
for RS were smoking at diagnosis and a stricturing or pen-
etrating disease phenotype. PA did not appear to have any 
significant influence on rates of first or repeat RS. Ileal 
disease location at diagnosis was not an independent risk 
factor for RS after controlling for smoking status at diag-
nosis and phenotype. 
 Analyses of data gathered in the SIBDC, one of the larg-
est nationwide IBD cohorts in Europe, led to the confir-
mation of observations made in previous observational 
studies in other countries concerning the high risk of un-
dergoing intestinal resection for CD patients during their 
lifetime disease course. The cumulative risk of surgery af-
ter diagnosis has been estimated to be around 80%  [10, 12, 
13, 21, 22] and the very recent observations from the pop-
ulation-based Olmsted County also confirm surgery rates 
found after 20 years of disease duration in our study  [23] . 
When comparing the characteristics of the population of 
postoperative patients, we observed that mean age at first 
intestinal resection was nearly 10 years higher compared 
to other cohorts  [24] , which may indicate either that a sig-
nificant effort has been made and achieved to delay the 
Table 3.  Uni- and multivariate Cox regression showing crude and adjusted HRs and 95% CI for RS
Crude HR
(95% CI)
p value Adjusted HR
(95% CI)
p value
Gender
Male 1.00
Female 1.01 (0.83–1.23) 0.911
Age at diagnosis
A1 (≤16) 1.00
A2 (17–40) 1.15 (0.85–1.56) 0.374
A3 (>40) 1.18 (0.81–1–71) 0.398
Smoking status at diagnosis
No 1.00 1.00
Yes 1.36 (1.12–1.66) 0.002 1.33 (1.08–1.64) 0.006
Disease location at diagnosis
L1 (terminal ileum) 1.00 1.00
L2 (colonic) 0.56 (0.41–0.78) <0.001 0.74 (0.53–1.03) 0.075
L3 (ileocolonic) 1.12 (0.87–1.44) 0.358 1.08 (0.84–1.40) 0.550
L4 (upper GI tract only) 1.67 (0.61–4.55) 0.317 2.39 (0.87–6.56) 0.090
Disease phenotype
B1 (non-stricturing/non-penetrating) 1.00 1.00
B1p (non-stricturing/non-penetrating with perianal disease) 1.56 (0.95–2.55) 0.080 1.47 (0.87–2.46) 0.148
B2 (stricturing) 4.94 (3.64–6.69) <0.001 4.11 (2.99–5.66) <0.001
B2p (stricturing with perianal disease) 6.10 (4.22–8.81) <0.001 4.91 (3.34–7.22) <0.001
B3 (penetrating) 5.21 (3.81–7.14) <0.001 4.58 (3.30–6.34) <0.001
B3p (penetrating with perianal disease) 4.45 (3.10–6.38) <0.001 3.53 (2.30–5.22) <0.001
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time to first RS, or that the disease remained undetected 
for a longer period before diagnosis  [25] , which might be 
the case for ileal diseases  [26] . The proportion of CD 
smokers at diagnosis was comparable to previous observa-
tions  [27] , and was a determinant for RS, but not for re-
peated surgery, which confirms results found in some 
studies  [28, 29] , but contradicted others  [21] . The propor-
tion of patients who still smoked at the time of inclusion 
was quite similar among those who underwent RS and 
those free of surgery but decreased as compared to those 
at diagnosis. We did not collect information on pack-
years of smoking and therefore were not able to stratify 
analyses to see if this observation persisted among low 
compared to heavy smokers. As we did not collect more 
precise chronology of smoking status, we were not able to 
see if smoking continuation after a RS episode had an ef-
fect on time to repeated surgery, or if the smoking status 
effect varied with concomitant drug exposition  [30] .
 In our study, we found that young age at diagnosis was 
not an independent risk factor for first RS, which was in 
opposition to studies in which age at diagnosis <40 was 
shown as being a high predictor for surgery  [31] . Accord-
ing to the Kaplan-Meier curves we drew, the effect ap-
peared to differ however according to duration of disease. 
Our observations may be related to modification in drug 
treatments over time. Indeed, young diagnosed patients 
with a short disease duration may have been treated ear-
lier more aggressively than in the past. Therefore, their 
outcome, in terms of need for RS, may have been delayed 
compared to patients diagnosed later.
 Penetrating disease was found to be a strong risk fac-
tor for surgery and for repeat RS, as found in previous 
studies  [14, 21, 31–33] conducted in Europe. PA did not 
appear, however, to modify rates of RS to a large extent, 
showing that aggressive disease presentation by itself 
plays a major role in the need for resective surgery. We 
observed from Kaplan-Meier curves that having an iso-
lated colonic disease seemed to delay the time to first RS 
compared to those with an ileal disease involvement; 
however, we did not find any major effect of disease lo-
cation distinguishable anymore in the multivariate Cox 
analysis. Upper gastrointestinal disease was not frequent 
in our cohort, therefore its influence on first or repeat 
RS could not been assessed with sufficient precision.
 Our study used data from a cohort study, including 
patients followed up in tertiary centers, but also in re-
gional hospitals and private practices; it may then be 
considered as a ‘snapshot’ of CD patients at a national 
Table 4.  Uni- and multivariate Cox regression showing crude and adjusted HRs and 95% CI for repeat surgery
Crude HR
(95% CI)
p value Adjusted HR
(95% CI)
p value
Gender
Male 1.00
Female 0.97 (0.68–1.39) 0.886
Age at diagnosis
A1 (≤16) 1.00
A2 (17–40) 0.63 (0.40–0.99) 0.047
A3 (>40) 0.49 (0.24–1.01) 0.054
Smoking status at diagnosis
No 1.00
Yes 0.91 (0.63–1.31) 0.635
Disease location at diagnosis
L1 (terminal ileum) 1.00
L2 (colonic) 0.58 (0.29–1.16) 0.122
L3 (ileocolonic) 0.86 (0.54–1.36) 0.515
L4 (upper GI tract only) 1.35 (0.18–10.0) 0.770
Disease phenotype
B1 (non-stricturing/non-penetrating) 1.00 1.00
B1p (non-stricturing/non-penetrating with perianal disease) 1.19 (0.43–3.29) 0.732 1.19 (0.43–3.29) 0.732
B2 (stricturing) 1.56 (0.76–3.21) 0.227 1.56 (0.76–3.21) 0.227
B2p (stricturing with perianal disease) 2.04 (0.95–4.40) 0.068 2.04 (0.95–4.40) 0.068
B3 (penetrating) 2.24 (1.10–4.55) 0.026 2.24 (1.10–4.45) 0.026
B3p (penetrating with perianal disease) 3.17 (1.54–6.55) 0.002 3.17 (1.54–6.55) 0.002
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level. Selection bias may have occurred due to the fact 
that 60% of the patients were recruited in tertiary cen-
ters, thus may have had more severe disease characteris-
tics. Our results show that the proportion of patients 
with a type 5 (biological) drug exposure history is higher 
in the group of patients that had repeat surgery. We 
might assume that biological therapies have been used 
too late in severely ill patients who could thus not be pre-
vented from repeat surgery. Using biological therapies at 
an earlier stage would have played a preventive role on 
surgery, as shown in previous studies  [34] ; this question 
will be investigated in a future prospective study. The 
demographics and patient clinical characteristics were, 
however, observed to be close to those found in prior 
European population-based studies, which indicates 
that our study population is likely closely representative 
of the general CD population followed up by gastroen-
terologists. Data were gathered by study nurses or physi-
cians trained in data recording, using dedicated clinical 
report forms designed specifically for the purpose of the 
study. This contributed to homogeneous data collection 
in terms of data types and definitions. Information bias 
could thus be minimized.
 CD patients included in the SIBDC cohort were shown 
to present a very high risk of RS. Stricturing and penetrat-
ing disease patterns as well as smoking at diagnosis in-
creased the risk of surgery, whereas isolated colonic dis-
ease and non-stricturing/non-penetrating disease pat-
terns tend to lower this risk. 
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